Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

​ Conditions: Adenocarcinoma; Prostate Cancer; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type Interventions: Biological: TriAdeno vaccine; Drug: N-803 Sponsors: National Cancer Institute (NCI) Not yet recruiting Conditions:...